Key result
Repeat AF ablation linked to ~56% lower 5-year mortality vs. antiarrhythmic drugs.
Why the study?
Real-world long-term data on clinical outcomes of rhythm control strategies in patients with recurrent AF after catheter ablation remain limited.
Does repeat catheter ablation improve clinical outcomes compared to antiarrhythmic drug therapy in adult patients with recurrent atrial fibrillation after index catheter ablation?
Cohort (n=4,056)
Yes
Does repeat catheter ablation improve clinical outcomes compared to antiarrhythmic drug therapy in adult patients with recurrent atrial fibrillation after index catheter ablation?
Hazard Ratio: 0.44 (95% CI 0.27–0.72)
Absolute Event Rate: 3.3% vs 8.2%
p-value: p=<0.01
In patients with recurrent atrial fibrillation after an initial ablation, repeat catheter ablation is associated with significantly lower long-term risks of mortality, hospitalization, and heart failure exacerbation compared to antiarrhythmic drug therapy.
Repeat ablation may lower mortality in recurrent AF; leaves open whether RCTs will confirm benefit before practice change.
BACKGROUND: Recurrence of symptomatic atrial fibrillation (AF) after catheter ablation (CA) is not uncommon. However, real-world long-term data on clinical outcomes of rhythm control strategies in patients with recurrent AF after CA remain limited. METHODS: Using the TriNetX database, we identified adult patients (≥18 years) with recurrent AF after index CA. A 3-month blanking period was applied, during which no rhythm-control therapy was received. Patients were classified into two groups: repeat CA or initiation of antiarrhythmic drug (AAD) therapy. Propensity score matching (PSM) was performed to balance baseline characteristics. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Outcomes included all-cause mortality, all-cause hospitalization, heart failure (HF) exacerbation, ischemic stroke, and major bleeding over 5 years. RESULTS: Among 4,056 patients with recurrent AF post-CA, 17.2% underwent repeat CA. After PSM, 697 patients in the repeat CA group (mean age 68.9 ± 9.6 years; 35.7% female) and 697 in the AAD group (mean age 68.4 ± 10.0 years; 37.6% female) were analyzed. Repeat CA was associated with lower all-cause mortality (3.3% vs 8.2%; HR 0.44; 95% CI, 0.27-0.72; P < 0.01), all-cause hospitalization (42.8% vs 56.4%; HR 0.71; 95% CI, 0.61-0.82; P < 0.01) and HF exacerbation (12.5% vs 24.8%; HR 0.50; 95% CI, 0.39-0.64; P < 0.01). No differences were observed in ischemic stroke (5.3% vs 4.7%; HR 1.22; 95% CI, 0.77-1.96; P = 0.40) or major bleeding (4.6% vs 6.2%; HR 0.82; 95% CI, 0.52-1.29; P = 0.39). CONCLUSIONS: Repeat CA was associated with lower mortality, hospitalization, and HF exacerbation over 5 years.
No takes yet. Share an insight, caveat, or question.
Yeo et al. (2026) conducted a cohort in Recurrent atrial fibrillation (n=4,056). Repeat catheter ablation vs. Antiarrhythmic drug (AAD) therapy was evaluated on All-cause mortality (HR 0.44, 95% CI 0.27-0.72, p=<0.01). Repeat catheter ablation was associated with a significantly lower risk of all-cause mortality (HR 0.44) compared to antiarrhythmic drug therapy over 5 years in patients with recurrent atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: